$SGMO to speak about Unlocking the Uncommon: "#Accelerating Cell & Gene Therapies for Rare Diseases" @ bio2026 , June 23 also #Astellas Chad Diehl , Legal Team Lead, #Licensing & #Acquisitions and Alliance Management talking about: "closing #deals in uncertain times"

$SGMO in a week, we will know!

$SGMO TX200 timeline is becoming increasingly difficult to ignore. • Nov 2023: Sangamo says it is actively seeking a partner/external investment for its CAR-Treg programs. • Mar 2024: Sangamo reiterates it is continuing to seek a partner and does not plan to advance the program alone. • Aug 2025: TX200 reports encouraging Phase 1/2 data: ✅ No biopsy-proven acute rejection ✅ No treatment-related SAEs ✅ CAR-Treg persistence ✅ Evidence of immune tolerance in graft tissue ✅ Most higher-dose patients tapered to tacrolimus monotherapy • 2025-2026: ClinicalTrials.gov results package remains active with SIX submission/QC cycles extending through June 2026. • June 2026: Sangamo hires Raymond James to explore strategic alternatives and didnot include tx200 program in the list What stands out to me: Since reiterating the partnering strategy in March 2024, management did not once talk abt TX200 program on earnings calls, even after the encouraging August 2025 data update. First submission: May 2025 Additional submissions: Dec 2025, Jan 2026, Feb 2026, May 2026, Jun 2026 This shows the results package has been actively worked on for over a year. TX200 remains one of the most underappreciated assets in the sangamo pipeline

$SGMO up 30% at .20

Happy Birthday to the GOAT. Looking forward to celebrating later today at the UFC fight!

🚨 BREAKING: Massive crowds are flooding the streets in towns and cities across the UK, demanding an end to mass migration. The British revolution has begun.

The writing is on the wall!

$SGMO to speak about Unlocking the Uncommon: "#Accelerating Cell & Gene Therapies for Rare Diseases" @ bio2026 , June 23 also #Astellas Chad Diehl , Legal Team Lead, #Licensing & #Acquisitions and Alliance Management talking about: "closing #deals in uncertain times"

$SGMO "I have been doing drug development for 27 years and this is the #most #beautiful #medicine I have ever seen" "ballance of effectiveness and safety" "its a very rare thing to see so much benefit" "most beautifil medicine" now at auction starting @ $25M offer anyone more?

Inside #Astellas 5-year strategy to counter Xtandi patent cliff "We will pursue rather derisked, risk-sharing type of structure with #partners" Astellas "That would look pretty much like a $SGMO Fabry deal , probably ex  US , for Asia and maybe Europe." fiercepharma.com/pharma/not-…

#Astellas says "We see #more platform #development together with (them) Sangamo $SGMO to actually create the next generation of gene therapy” ...#neuromuscular disease strategy... medcitynews.com/2025/01/aste…

#Astellas calling out #RESCUE BD • Protect near-term revenue through a large-scale asset/ company acquisition • Focus on near-launch or marketed assets re $SGMO already partnered STAC-BBB Fabry = "Focus on near-launch" ? www.astellas_csp2026_presentation_20260526_en.pdf

2/2 After years of safety concerns in early gene therapy trials, ARM member Astellas is developing a new therapy for XLMTM using a modified AAV virus that shows early promise. This shows how developers and the scientific community are adapting to improve safety and efficacy.

IRAN CONFIRMS US IRAN DEAL #BREAKING

$SGMO A new guide from the #Fabry International Network is aimed at young adults with Fabry disease and clearly illustrates how debilitating the condition can be, far beyond its purely medical symptoms. Those affected often have to live with chronic pain, fatigue, gastrointestinal problems, heart and kidney issues, as well as uncertainty about the long-term course of the disease, from a young age. Added to this are challenges in the transition from paediatric to adult healthcare, as well as in education, career choices, relationships and family planning. The guide addresses precisely these issues and aims to help young people shape their daily lives independently and connect with others affected by the condition. The publication makes it clear that Fabry is not merely a rare metabolic disorder, but one that has a lasting impact on many areas of life. Against this backdrop, it is understandable why there is such great hope for new therapeutic approaches. A successful one-off gene therapy such as Sangamo’s ST-920 could fundamentally change the lives of many patients: instead of lifelong regular treatments, a long-term or even permanent restoration of the missing enzyme activity could be achieved. This would offer the prospect of significantly reducing the burden of the disease, organ complications and the need for treatment, and enable those affected to lead a much freer and more predictable life. fabrydiseasenews.com/news/ne…

The symptoms of #Fabry is strangely similar to $SGMO stock owner's disease ... chronic pain, fatigue, gastrointestinal problems, heart and kidney issues, and uncertainty about the long-term course of the disease... the only cure is Sandy injecting some cash into the lifeline

Totally get you. But honestly… been a shareholder for a cupla years now and kinda sick of all the “ifs”. They gotta sh!t or get off the pot!

HCW raises $PGEN ($4.40) Price Target to $14 on Papzimeos market exclusivity re competitor = $INO

$PGEN FDA grants orphan drug exclusivity for PAPZIMEOS for the treatment of adults with recurrent respiratory papillomatosis #7year period of PAPZIMEOS market #exclusivity is effective through August 14, 2032 RIP $INO